Merck KGAA/Pfizer Discontinue Phase III Avelumab/Talazoparib Combo Study In Ovarian Cancer
Executive Summary
The changing competitive landscape in ovarian cancer, as well as disappointing earlier results in the condition, has led to the big pharma alliance ending the Phase III JAVELIN Ovarian PARP 100 study.
You may also be interested in...
First-Line Bavencio Bladder Cancer OK Boosts Merck KGaA
Pfizer-partnered Bavencio has struggled to compete with other checkpoint inhibitors like Keytruda, Opdivo, Imfinzi and Tecentriq, but could carve out a lucrative niche in first-line urothelial carcinoma.
Roche's Tecentriq Disappoints In Ovarian Cancer Study
PD-1/PDL-1 inhibitors have not proved effective for ovarian cancer on their own or in combinations. Now Roche's Tecentriq, combined with the firm's blockbuster Avastin, has suffered a similar fate to Merck KGaA and Pfizer's Bavencio in failing to improve survival.
Pfizer's Talzenna To Compete With AZ's Lynparza In Breast Cancer After EU Okay
European approval for its PARP inhibitor to treat BRCA-mutated breast cancer is clearly good news for the US giant but Talzenna will likely remain in Lynparza’s shadow in the near term.